Fig. 3.

IFN displaces Cx43 from enterocyte lipid rafts; the phorbol ester PMA restores Cx43 to lipid rafts after treatment with IFN. A, upper blot: SDS-PAGE of Cx43 in lipid raft-enriched fractions that were purified from IEC-6 cells that had been either untreated (Ctrl), or treated with IFN in the absence (IFN) or presence of PMA (IFN + PMA) or PMA alone (PMA). Lower blot: SDS-PAGE showing the expression of Cx43 in whole cell lysate of IEC-6 cells treated as above. Representative of at least 5 separate experiments. B: quantification of 3 separate experiments similar to those in A, showing means and SE. *P < 0.05 vs. control by ANOVA. C, upper blot: SDS-PAGE showing the expression of Cav-1 in IEC-6 cells that had undergone immunoprecipitation with anti-Cx43 antibodies as described in methods. Cells had been treated with IFN and/or PMA as in A. Lower blot: the expression of Cx43 in the anti-Cx43 immunoprecipitate. Representative of at least 3 separate experiments. D: quantification of 3 separate experiments similar to those in C, showing means and SE. *P < 0.05 vs. control by ANOVA. E: expression of Cav-1 in whole cell lysates purified from IEC-6 cells under the conditions indicated, representative of 3 separate experiments. F: quantification of 3 separate experiments similar to those in E, showing means and SE. *P < 0.05 vs. control by ANOVA.